Golden Meditech is pleased to announce that the sale of 65.4% of the issued share capital of China Cord Blood Corporation to Nanjing Yingpeng Huikang Medical Industry Investment Partnership has been completed.
| |
| [31-January-2018] |
| HONG KONG, Jan. 31, 2018 /PRNewswire/ -- Golden Meditech, a leading integrated healthcare enterprise in China, is pleased to announce that the sale of 65.4% of the issued share capital of China Cord Blood Corporation to Nanjing Yingpeng Huikang Medical Industry Investment Partnership (Limited Partnership)* has been completed. Details have been published by the Company in accordance with the Rules Governing the Listing of Securities on the Stock Exchange of Hong Kong Limited and posted on the Company’s website as follows: http://www.goldenmeditech.com/eng/ir/announcements.php?year=2018 *For identification purpose only. About Golden Meditech Holdings Limited (SEHK stock code: 00801) Golden Meditech (www.goldenmeditech.com) is a leading integrated-healthcare enterprise in China. It is a first-mover in China, having established its dominant positions in several markets including the medical devices market and the hospital management market in the healthcare industry, thanks to its strengths in innovation and market expertise and the ability to capture emerging market opportunities. Going forward, Golden Meditech will continue to pursue a leading position in China’s healthcare industry both through organic growth and strategic expansion. View original content:http://www.prnewswire.com/news-releases/golden-meditech-completes-sale-of-equity-interest-in-china-cord-blood-corporation-300590973.html SOURCE Golden Meditech Holdings Limited | ||
Company Codes: HongKong:0801, OTC-PINK:GMDTY |
